World J Nephrol Urol

World Journal of Nephrology and Urology, ISSN 1927-1239 print, 1927-1247 online, Open Access

Article copyright, the authors; Journal compilation copyright, World J Nephrol Urol and Elmer Press Inc

Journal website https://wjnu.elmerpub.com

Review

Volume 15, Number 3, July 2026, pages 65-70

5-Alpha-Reductase Inhibitor for Benign Prostatic Hyperplasia: A Review of Volume-Selected Therapy and Safe Prostate Cancer Detection

↓ **Table 1.** Volume-Selected Treatment Framework for LUTS/BPH When Considering Dutasteride-Based Therapy
Clinical phenotype	Preferred treatment emphasis	Evidence-based rationale	Monitoring implications
AUR: acute urinary retention; BPH: benign prostatic hyperplasia; DRE: digital rectal examination; LUTS: lower urinary tract symptoms; PSA: prostate-specific antigen; 5-ARI: 5-alpha-reductase inhibitor.
Moderate-to-severe LUTS without clear enlargement (e.g., small prostate or low PSA-volume proxy)	Prioritize symptom-directed therapy such as an alpha-1 blocker; avoid routine 5-ARI initiation unless enlargement or increased risk is demonstrated.	5-ARI benefit is less predictable in small glands; the threshold is benefit–risk selection rather than a cancer-generation boundary [1, 2].	Assess baseline PSA/DRE according to age and cancer-risk context; do not start dutasteride merely to treat irritative LUTS without enlargement.
Demonstrable enlargement or increased progression risk (e.g., volume > 40 mL, palpable enlargement, or PSA proxy suggesting enlarged gland)	Consider dutasteride monotherapy when long-term risk reduction is a primary goal and rapid symptom relief is not essential.	5-ARIs reduce prostate volume, PSA, AUR, and BPH-related surgery risk in appropriately selected men [1, 3–5].	Record baseline PSA and prostate-size evidence; repeat PSA around 6 months and label the new on-treatment baseline.
Enlarged prostate plus bothersome moderate-to-severe LUTS requiring rapid relief and long-term risk reduction	Consider dutasteride–tamsulosin when the patient needs early symptom relief and long-term risk reduction and accepts the adverse-effect profile.	CombAT enrolled an enlarged-prostate, higher-risk population and showed durable reductions in AUR and surgery compared with tamsulosin alone [1, 6].	Apply dutasteride PSA rules because PSA suppression is driven by the 5-ARI component [3, 4].
Cancer suspicion at baseline or unexplained PSA abnormality before treatment	Defer or pause 5-ARI initiation until cancer risk is appropriately assessed.	Starting dutasteride before evaluation can complicate PSA interpretation and delay referral if the baseline is not documented [3, 4, 15].	Clarify DRE, PSA trend, PSA density where available, and MRI/biopsy pathway before long-term BPH pharmacotherapy.
Stable long-term responder on dutasteride or dutasteride–tamsulosin	Continue if symptom benefit exceeds harms; periodically review whether combination therapy remains necessary.	Benefits are long-term and phenotype-dependent; adverse effects and comorbidity burden may change over time [1, 6, 21–24].	Ensure every PSA request and referral letter states current or prior 5-ARI exposure.

↓ Table 1. Volume-Selected Treatment Framework for LUTS/BPH When Considering Dutasteride-Based Therapy

Clinical phenotype

Preferred treatment emphasis

Evidence-based rationale

Monitoring implications

AUR: acute urinary retention; BPH: benign prostatic hyperplasia; DRE: digital rectal examination; LUTS: lower urinary tract symptoms; PSA: prostate-specific antigen; 5-ARI: 5-alpha-reductase inhibitor.

Moderate-to-severe LUTS without clear enlargement (e.g., small prostate or low PSA-volume proxy)

Prioritize symptom-directed therapy such as an alpha-1 blocker; avoid routine 5-ARI initiation unless enlargement or increased risk is demonstrated.

5-ARI benefit is less predictable in small glands; the threshold is benefit–risk selection rather than a cancer-generation boundary [1, 2].

Assess baseline PSA/DRE according to age and cancer-risk context; do not start dutasteride merely to treat irritative LUTS without enlargement.

Demonstrable enlargement or increased progression risk (e.g., volume > 40 mL, palpable enlargement, or PSA proxy suggesting enlarged gland)

Consider dutasteride monotherapy when long-term risk reduction is a primary goal and rapid symptom relief is not essential.

5-ARIs reduce prostate volume, PSA, AUR, and BPH-related surgery risk in appropriately selected men [1, 3–5].

Record baseline PSA and prostate-size evidence; repeat PSA around 6 months and label the new on-treatment baseline.

Enlarged prostate plus bothersome moderate-to-severe LUTS requiring rapid relief and long-term risk reduction

Consider dutasteride–tamsulosin when the patient needs early symptom relief and long-term risk reduction and accepts the adverse-effect profile.

CombAT enrolled an enlarged-prostate, higher-risk population and showed durable reductions in AUR and surgery compared with tamsulosin alone [1, 6].

Apply dutasteride PSA rules because PSA suppression is driven by the 5-ARI component [3, 4].

Cancer suspicion at baseline or unexplained PSA abnormality before treatment

Defer or pause 5-ARI initiation until cancer risk is appropriately assessed.

Starting dutasteride before evaluation can complicate PSA interpretation and delay referral if the baseline is not documented [3, 4, 15].

Clarify DRE, PSA trend, PSA density where available, and MRI/biopsy pathway before long-term BPH pharmacotherapy.

Stable long-term responder on dutasteride or dutasteride–tamsulosin

Continue if symptom benefit exceeds harms; periodically review whether combination therapy remains necessary.

Benefits are long-term and phenotype-dependent; adverse effects and comorbidity burden may change over time [1, 6, 21–24].

Ensure every PSA request and referral letter states current or prior 5-ARI exposure.

↓ **Table 2.** PSA and Prostate-Cancer Surveillance Pathway for Men Receiving Dutasteride or Dutasteride–Tamsulosin
Time point or event	Action	Interpretation and escalation
DRE: digital rectal examination; MRI: magnetic resonance imaging; PI-RADS: Prostate Imaging Reporting and Data System; PSA: prostate-specific antigen; 5-ARI: 5-alpha-reductase inhibitor; LUTS: lower urinary tract symptoms.
Before treatment	Document LUTS severity, DRE, baseline PSA, prostate volume or PSA-volume proxy, urinalysis as appropriate, and reason for choosing a 5-ARI.	Do not use a future suppressed PSA without knowing the pre-treatment value; investigate suspicious DRE or PSA before therapy [3, 4].
First 0–6 months	Expect PSA to fall progressively; avoid reassurance from a partially suppressed PSA.	Dutasteride lowers mean PSA by about 50% by 6 months, so the transition period is not a cancer-exclusion period [3, 4].
Approximately 6 months	Repeat PSA and designate the result as the new on-treatment baseline or nadir reference point.	The value may be doubled for comparison with untreated thresholds, but nadir-based interpretation is essential [3, 4, 16].
Ongoing monitoring	Check PSA periodically and ensure all clinicians know the patient is taking a 5-ARI.	A stable low PSA is expected; a confirmed rise is the clinically important signal [3, 4, 16–18].
Confirmed PSA increase from nadir	Repeat PSA to confirm; review adherence, prostatitis, urinary retention, instrumentation, and laboratory variability; refer if unexplained.	A rise from the lowest on-treatment PSA may indicate prostate cancer, including high-grade disease, or non-adherence. It should not be ignored [3, 4, 17, 18].
Cancer-risk assessment after referral	Use MRI before biopsy when suspected organ-confined prostate cancer is being evaluated; biopsy strategy should follow PI-RADS, PSA density, DRE, and patient risk.	MRI-first pathways reduce unnecessary biopsy but depend on timely recognition of the PSA signal in 5-ARI users [19].
After discontinuation	Continue surveillance according to clinical risk and recognize that PSA may return toward baseline over months.	Australian product information notes total serum PSA returns to baseline within 6 months after stopping dutasteride [3, 4].

↓ Table 2. PSA and Prostate-Cancer Surveillance Pathway for Men Receiving Dutasteride or Dutasteride–Tamsulosin

Time point or event

Action

Interpretation and escalation

DRE: digital rectal examination; MRI: magnetic resonance imaging; PI-RADS: Prostate Imaging Reporting and Data System; PSA: prostate-specific antigen; 5-ARI: 5-alpha-reductase inhibitor; LUTS: lower urinary tract symptoms.

Before treatment

Document LUTS severity, DRE, baseline PSA, prostate volume or PSA-volume proxy, urinalysis as appropriate, and reason for choosing a 5-ARI.

Do not use a future suppressed PSA without knowing the pre-treatment value; investigate suspicious DRE or PSA before therapy [3, 4].

First 0–6 months

Expect PSA to fall progressively; avoid reassurance from a partially suppressed PSA.

Dutasteride lowers mean PSA by about 50% by 6 months, so the transition period is not a cancer-exclusion period [3, 4].

Approximately 6 months

Repeat PSA and designate the result as the new on-treatment baseline or nadir reference point.

The value may be doubled for comparison with untreated thresholds, but nadir-based interpretation is essential [3, 4, 16].

Ongoing monitoring

Check PSA periodically and ensure all clinicians know the patient is taking a 5-ARI.

A stable low PSA is expected; a confirmed rise is the clinically important signal [3, 4, 16–18].

Confirmed PSA increase from nadir

Repeat PSA to confirm; review adherence, prostatitis, urinary retention, instrumentation, and laboratory variability; refer if unexplained.

A rise from the lowest on-treatment PSA may indicate prostate cancer, including high-grade disease, or non-adherence. It should not be ignored [3, 4, 17, 18].

Cancer-risk assessment after referral

Use MRI before biopsy when suspected organ-confined prostate cancer is being evaluated; biopsy strategy should follow PI-RADS, PSA density, DRE, and patient risk.

MRI-first pathways reduce unnecessary biopsy but depend on timely recognition of the PSA signal in 5-ARI users [19].

After discontinuation

Continue surveillance according to clinical risk and recognize that PSA may return toward baseline over months.

Australian product information notes total serum PSA returns to baseline within 6 months after stopping dutasteride [3, 4].